Geode Capital Management’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $21.4M | Buy |
1,881,960
+157,592
| +9% | +$1.8M | ﹤0.01% | 1918 |
|
|
2025
Q1 | $20.5M | Buy |
1,724,368
+139,241
| +9% | +$1.65M | ﹤0.01% | 1886 |
|
|
2024
Q4 | $29.9M | Buy |
1,585,127
+137,087
| +9% | +$2.58M | ﹤0.01% | 1741 |
|
|
2024
Q3 | $32.5M | Buy |
1,448,040
+126,306
| +10% | +$2.84M | ﹤0.01% | 1706 |
|
|
2024
Q2 | $27.6M | Buy |
1,321,734
+221,399
| +20% | +$4.62M | ﹤0.01% | 1747 |
|
|
2024
Q1 | $16.2M | Buy |
1,100,335
+19,812
| +2% | +$291K | ﹤0.01% | 2046 |
|
|
2023
Q4 | $11.2M | Buy |
1,080,523
+35,238
| +3% | +$364K | ﹤0.01% | 2280 |
|
|
2023
Q3 | $8.22M | Buy |
1,045,285
+67,234
| +7% | +$529K | ﹤0.01% | 2381 |
|
|
2023
Q2 | $9.77M | Buy |
978,051
+47,360
| +5% | +$473K | ﹤0.01% | 2300 |
|
|
2023
Q1 | $8.26M | Buy |
930,691
+36,475
| +4% | +$324K | ﹤0.01% | 2378 |
|
|
2022
Q4 | $9.82M | Buy |
894,216
+77,754
| +10% | +$854K | ﹤0.01% | 2278 |
|
|
2022
Q3 | $10.6M | Buy |
816,462
+43,168
| +6% | +$562K | ﹤0.01% | 2203 |
|
|
2022
Q2 | $9.8M | Buy |
773,294
+120,800
| +19% | +$1.53M | ﹤0.01% | 2268 |
|
|
2022
Q1 | $9.14M | Buy |
652,494
+30,947
| +5% | +$434K | ﹤0.01% | 2412 |
|
|
2021
Q4 | $18M | Sell |
621,547
-9,151
| -1% | -$265K | ﹤0.01% | 2024 |
|
|
2021
Q3 | $18.9M | Buy |
630,698
+235,941
| +60% | +$7.07M | ﹤0.01% | 1998 |
|
|
2021
Q2 | $10.5M | Buy |
394,757
+71,237
| +22% | +$1.89M | ﹤0.01% | 2419 |
|
|
2021
Q1 | $10.1M | Buy |
323,520
+124,287
| +62% | +$3.86M | ﹤0.01% | 2361 |
|
|
2020
Q4 | $6.55M | Buy |
199,233
+15,331
| +8% | +$504K | ﹤0.01% | 2443 |
|
|
2020
Q3 | $6.42M | Buy |
+183,902
| New | +$6.42M | ﹤0.01% | 2249 |
|